Sphingosine-1-phosphate essentially free of L-threo isomer
US5663404A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 12, 1995 |
| Grant date | Sep 2, 1997 |
| Priority date | — |
| Expiry date | Jan 12, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/173
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of inhibiting tumor cell chemotactic and/or chemoinvasion motility comprising contacting the tumor cell with an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting phagokinetic activity of tumor cells and neutrophils comprising contacting the cells with a phagokinetic inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting tumor cell metastasis comprising administering to a host in need of treatment a metastasis inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent. A method of inhibiting inflammation due to motility and invasion into blood vessel walls of neutrophils comprising administering to a host in need of treatment an inflammation inhibitory…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.